Seres Therapeutics, Inc. (MCRB) — Financial statements
Income statement, balance sheet, and cash flow for Seres Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.79 | 0.00 | 0.00 | 0.00↓100.0% | 145 | |
| Cost of Revenue | 4↑17.0% | 4 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -3↑5.3% | -4 | 0.00 | 0.00↓100.0% | 145 | |
| Operating Expenses | ||||||
| R&D Expenses | 49↓24.1% | 65↓45.1% | 118↑7.2% | 110↓22.7% | 142 | |
| General & Administrative Expenses | 39↓26.4% | 53↓31.4% | 78↑10.3% | 70↑1.4% | 69 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 39↓26.4% | 53↓31.4% | 78↑10.3% | 70↑1.4% | 69 | |
| Other Expenses | 2 | 0.00 | 0.00 | 0.00↑100.0% | -2 | |
| Operating Expenses | 91↓23.1% | 118↓39.6% | 195↑8.4% | 180↓14.1% | 209 | |
| Total Costs & Expenses | 95↓21.9% | 121↓37.8% | 195↑8.4% | 180↓14.1% | 209 | |
| Operating Results | ||||||
| Operating Income | -94↑22.5% | -121↑37.8% | -195↓8.4% | -180↓179.0% | -64 | |
| Depreciation & Amortization | 4↓24.4% | 5↓12.4% | 6↓5.8% | 7↑11.5% | 6 | |
| EBITDA | -90↑25.3% | -120↑33.7% | -181↓6.1% | -171↓201.4% | -57 | |
| EBIT | -94↑25.3% | -126↑33.0% | -188↓5.7% | -178↓183.3% | -63 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↓43.9% | 4↑167.5% | -6↓98.3% | -3↓7305.0% | -0.04 | |
| Interest Income | 2↓43.9% | 4↓45.7% | 7↑138.8% | 3↑6.6% | 3 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 13↑118.9% | 6↑106.9% | 3 | |
| Non-Operating Income | 0.00↓100.0% | 4↑159.9% | -7↓216.0% | -2↓28.9% | -2 | |
| Other Income / Expenses | 100↑2336.7% | -4↓189.7% | 5↑235.5% | -4↓238.0% | -1 | |
| Income Before Tax | 6↑104.5% | -126↑33.8% | -190↓3.6% | -184↓179.9% | -66 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 6↑104.5% | -126↑33.8% | -190↓3.6% | -184↓179.9% | -66 | |
| Net Income from Discontinued Operations | 0.00↓100.0% | 126↑64.8% | 76↑214.8% | -67 | 0.00 | |
| Net Income | 6↑4088.2% | 0.14↑100.1% | -114↑54.5% | -250↓281.5% | -66 | |
| Bottom-Line Net Income | 6↑103.9% | -147↓28.9% | -114↑54.5% | -250↓281.5% | -66 | |
| EPS (Basic) | 0.64↑103.4% | -18.86↓6.1% | -17.77↑61.6% | -46.29↓223.7% | -14.30 | |
| EPS (Diluted) | 0.64↑103.4% | -18.86↓6.1% | -17.77↑61.6% | -46.29↓223.7% | -14.30 | |
| Weighted Average Shares | 9↑14.0% | 8↑21.4% | 6↑18.4% | 5↑17.9% | 5 | |
| Weighted Average Diluted Shares | 9↑14.2% | 8↑21.4% | 6↑18.4% | 5↑17.9% | 5 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.